Castle Biosciences (CSTL) Cash & Equivalents (2018 - 2026)

Castle Biosciences has disclosed Cash & Equivalents across 9 years of filings, most recently posting $63.8 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $63.8 million, down 28.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $63.8 million (down 28.87% YoY), and the FY2025 annual result was $116.7 million, down 2.49% from the prior year.
• Cash & Equivalents came in at $63.8 million for Q1 2026 at Castle Biosciences, down from $116.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $309.0 million in Q1 2022 to a low of $63.8 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $95.9 million (2023), against an average of $121.3 million.
• Across the five-year window, Cash & Equivalents sank 64.89% in 2023 and advanced 21.11% in 2024, its largest moves.
• Castle Biosciences' Cash & Equivalents stood at $122.9 million in 2022, then slipped by 19.61% to $98.8 million in 2023, then gained by 21.11% to $119.7 million in 2024, then retreated by 2.49% to $116.7 million in 2025, then plunged by 45.34% to $63.8 million in 2026.
• The last three Cash & Equivalents figures came in at $63.8 million (Q1 2026), $116.7 million (Q4 2025), and $85.6 million (Q3 2025), per Business Quant data.